Use of a folding model and in situ spectroscopic techniques for rational formulation development and stability testing of monoclonal antibody therapeutics.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Pharmacy and Science

• Publication date

  2010-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/jps.21938PMID 19798762PMCID PMC5119463
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Principles, approaches, and challenges for predicting protein aggregation rates and shelf life.

  2009cited by this paper
• Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality.

  2009cited by this paper
• Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies.

  2008cited by this paper
• Highly concentrated monoclonal antibody solutions: direct analysis of physical structure and thermal stability.

  2007cited by this paper
• Non-native aggregation of alpha-chymotrypsinogen occurs through nucleation and growth with competing nucleus sizes and negative activation energies.

  2007cited by this paper
• Antibody structure, instability, and formulation.

  2007cited by this paper
• A Lumry-Eyring nucleated polymerization model of protein aggregation kinetics: 1. Aggregation with pre-equilibrated unfolding.

  2007cited by this paper
• Protein aggregation and bioprocessing

  2006cited by this paper
• Aggregation kinetics of recombinant human FVIII (rFVIII).

  2005cited by this paper
• The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein.

  2000cited by this paper
• Liposomes as Formulation Excipients for Protein Pharmaceuticals: A Model Protein Study

  2000cited by this paper
• The effect of pH, hydrogen peroxide and temperature on the stability of human monoclonal antibody.

  1996cited by this paper
• Evidence for a molten globule state as a general intermediate in protein folding

  1990cited by this paper
• Differential scanning calorimetry of the irreversible thermal denaturation of thermolysin.

  1988cited by this paper

• A mechanistic marker-based screening tool to predict clinical immunogenicity of biologics

  2023cites this paper
• A survey of FDA Approved Monoclonal Antibodies and Fc-fusion Proteins for Manufacturing Changes and Comparability Assessment

  2023cites this paper
• Molecular characterization of linker and loop-mediated structural modulation and hinge motion in the C4-C5 domains of cMyBPC.

  2022cites this paper
• Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins

  2021cites this paper
• Review of the current state of protein aggregation inhibition from a materials chemistry perspective: special focus on polymeric materials

  2021cites this paper
• 19F Dark-State Exchange Saturation Transfer NMR Reveals Reversible Formation of Protein-Specific Large Clusters in High-Concentration Protein Mixtures

  2019cites this paper
• Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins.

  2018cites this paper
• Why the Immune System Should Be Concerned by Nanomaterials?

  2017cites this paper
• Electrophorèse capillaire couplée ou non à la spectrométrie de masse pour l’évaluation ou le contrôle qualité de protéines à visée thérapeutique

  2015cites this paper
• The Effect of Small Oligomeric Protein Aggregates on the Immunogenicity of Intravenous and Subcutaneous Administered Antibodies.

  2015cites this paper
• Limited aggregation behavior of β-conglycinin and its terminating effect on glycinin aggregation during heating at pH 7.0.

  2012cites this paper
• Relating particle formation to salt- and pH-dependent phase separation of non-native aggregates of alpha-chymotrypsinogen A.

  2012cites this paper
• The impact of glycosylation on monoclonal antibody conformation and stability

  2011cites this paper
• Ultraviolet spectroscopy as a tool in therapeutic protein development.

  2011cites this paper